Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Hoffman

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Harvard Magazine|September 1, 1983
The Darsee affairHarold N Cooledge, Robert L Hoffman, S Valerie Hoffman
Future Medicinal Chemistry|January 31, 2013
Lipophilic efficiency: the most important efficiency metric in medicinal chemistryKevin D Freeman-Cook, Robert L Hoffman, Ted W Johnson
Bioorganic & Medicinal Chemistry Letters|September 25, 2007
Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonistsJeffrey W Corbett, Mark R Rauckhorst, Fang Qian, et al.
Plos One|September 24, 2015
Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical UtilityRicardo Martinez, Alessandra Blasina, Jill F Hallin, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonistsMichael D Ennis, Robert L Hoffman, Nabil B Ghazal, et al.
Journal of Medicinal Chemistry|October 15, 2020
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19Robert L Hoffman, Robert S Kania, Mary A Brothers, et al.
Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Journal of Medicinal Chemistry|May 14, 2014
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutationsTed W Johnson, Paul F Richardson, Simon Bailey, et al.
Journal of Medicinal Chemistry|January 18, 2014
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinibQinhua Huang, Ted W Johnson, Simon Bailey, et al.
Cancer Cell|September 14, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitorKevin Freeman-Cook, Robert L Hoffman, Nichol Miller, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Harvard Magazine|September 1, 1983
The Darsee affairHarold N Cooledge, Robert L Hoffman, S Valerie Hoffman
Future Medicinal Chemistry|January 31, 2013
Lipophilic efficiency: the most important efficiency metric in medicinal chemistryKevin D Freeman-Cook, Robert L Hoffman, Ted W Johnson
Bioorganic & Medicinal Chemistry Letters|September 25, 2007
Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonistsJeffrey W Corbett, Mark R Rauckhorst, Fang Qian, et al.
Plos One|September 24, 2015
Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical UtilityRicardo Martinez, Alessandra Blasina, Jill F Hallin, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonistsMichael D Ennis, Robert L Hoffman, Nabil B Ghazal, et al.
Journal of Medicinal Chemistry|October 15, 2020
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19Robert L Hoffman, Robert S Kania, Mary A Brothers, et al.
Journal of Medicinal Chemistry|June 10, 2021
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of CancerKevin D Freeman-Cook, Robert L Hoffman, Douglas C Behenna, et al.
Journal of Medicinal Chemistry|May 14, 2014
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutationsTed W Johnson, Paul F Richardson, Simon Bailey, et al.
Journal of Medicinal Chemistry|January 18, 2014
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinibQinhua Huang, Ted W Johnson, Simon Bailey, et al.
Cancer Cell|September 14, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitorKevin Freeman-Cook, Robert L Hoffman, Nichol Miller, et al.
Pageof 1